Vitreomacular adhesion (VMA) does not affect the development of exudative age-related macula degeneration.
Vitreomacular adhesion (VMA) does not affect the development of exudative age-related macula degeneration, according to the results of a 4-year longitudinal study in Retina.
The prospective, longitudinal investigation, led by Dr Sebastian Waldstein, Department of Ophthalmology, Medical University of Vienna, Austria, included 49 patients with AMD who underwent optical coherence tomography (OCT) and fluorescein angiography (FA) every three months for four years.
Time-domain and spectral-domain OCT were used to assess vitreomacula adhesion. OCT and FA were also used to determine development of choroidal neovascularization (CNV). CNV incidences were compared in all patients, through the presence or absence of VMA.
Of the patients studied, nine presented with VMA at baseline and 18 patients experienced exudative changes during the observation period. Development of CNV was present in 33% of patients with pre-existing VMA and 38% in patients without VMA.
In VMA patients the mean interval from baseline to disease progression was 20 ± 19 months and 22 ± 13 months in patients without VMA. Rate of CNV development and time to disease progression were not significantly different between the groups.
AAO 2024: Detail outlined for Artificial Intelligence Innovation Center at Wilmer Eye Institute
October 24th 2024During a conversation at the American Academy of Ophthalmology annual meeting in Chicago, T.Y. Alvin Liu, MD, discussed plans for the James P. Gills Jr, MD, & Heather Gills Artificial Intelligence Innovation Center at the Wilmer Eye Institute at Johns Hopkins Medicine.
AAO 2024: Transient vision loss with Alexander Fein, MD
October 21st 2024Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might be needed to determine the best plan for care.